Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TRACY W DOBBS

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1104826148
CMS profile
185806
Location
KNOXVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$4,033.51

226 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,988.10 225
Education $45.41 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Novartis Pharmaceuticals Corporation $389.74 20
GENZYME CORPORATION $262.39 16
E.R. Squibb & Sons, L.L.C. $252.21 21
Amgen Inc. $243.26 13
Merck Sharp & Dohme LLC $214.76 10
AstraZeneca Pharmaceuticals LP $178.89 10
Janssen Biotech, Inc. $166.84 11
PFIZER INC. $135.65 10
EISAI INC. $123.68 8
Incyte Corporation $116.02 6
GlaxoSmithKline, LLC. $101.70 5
Genentech USA, Inc. $98.36 6
ABBVIE INC. $88.45 4
Daiichi Sankyo Inc. $88.09 4
Gilead Sciences, Inc. $87.68 5
Astellas Pharma US Inc $81.79 5
Exelixis Inc. $79.56 4
Rigel Pharmaceuticals, Inc. $77.06 5
Alexion Pharmaceuticals, Inc. $76.94 3
AVEO Pharmaceuticals, Inc. $75.89 2
BeiGene USA, Inc. $66.15 3
MorphoSys, US Inc. $64.53 2
Seagen Inc. $58.49 4
Lilly USA, LLC $56.39 3
Progenics Pharmaceuticals, Inc. $55.70 1
Sobi, Inc $51.36 3
EMD Serono, Inc. $48.17 3
Heron Therapeutics, Inc. $47.50 1
Myovant Sciences Inc. $46.33 3
Bayer HealthCare Pharmaceuticals Inc. $45.23 3
PUMA BIOTECHNOLOGY, INC. $41.23 2
ARRAY BIOPHARMA INC $39.85 2
Pharmacyclics LLC, an AbbVie Company $39.59 2
SECURA BIO, INC. $38.92 4
Karyopharm Therapeutics Inc. $36.53 2
Ipsen Biopharmaceuticals, Inc $33.55 2
JAZZ PHARMACEUTICALS INC. $32.90 2
Regeneron Healthcare Solutions, Inc. $32.52 2
Celgene Corporation $30.91 2
TerSera Therapeutics LLC $29.49 1
Coherus Biosciences Inc. $27.96 1
TG Therapeutics, Inc. $24.71 1
G1 Therapeutics, Inc. $23.23 1
Takeda Pharmaceuticals U.S.A., Inc. $18.40 1
EUSA Pharma (US) LLC $18.11 1
Foundation Medicine, Inc. $17.42 1
Boehringer Ingelheim Pharmaceuticals, Inc. $16.59 1
Kite Pharma, Inc. $15.62 1
Deciphera Pharmaceuticals Inc. $15.40 1
Epizyme, Inc., $11.90 1
Organon LLC $9.87 1

Page 4 of 5; records 151–200 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TRACY W DOBBS

NPI 1104826148 · CMS profile ID 185806

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

KNOXVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104826148?year=2022&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TRACY W DOBBS, NPI 1104826148, CMS profile ID 185806. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104826148?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). TRACY W DOBBS, NPI 1104826148, CMS profile ID 185806. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104826148?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
TRACY W DOBBS, NPI 1104826148, CMS profile ID 185806, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1104826148?year=2022&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

226 matching records · $4,033.51 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 226 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 226.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $20.1104/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915402597 CMS
AstraZeneca Pharmaceuticals LP $19.9204/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915261483 CMS
MorphoSys, US Inc. $17.1804/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962539509 CMS
EUSA Pharma (US) LLC $18.1104/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964300957 CMS
E.R. Squibb & Sons, L.L.C. $8.2704/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932785479 CMS
EISAI INC. $21.8604/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908094479 CMS
Janssen Biotech, Inc. $8.8604/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886549607 CMS
PFIZER INC. $12.6604/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949125861 CMS
GENZYME CORPORATION $16.1004/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938761543 CMS
Gilead Sciences, Inc. $18.5104/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929564435 CMS
Novartis Pharmaceuticals Corporation $21.1904/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893606233 CMS
Seagen Inc. $13.9204/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904099261 CMS
Pharmacyclics LLC, an AbbVie Company $19.1704/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890339455 CMS
Incyte Corporation $19.7504/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942962139 CMS
Janssen Biotech, Inc. $13.7704/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886549613 CMS
E.R. Squibb & Sons, L.L.C. $6.6104/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932785477 CMS
Merck Sharp & Dohme LLC $20.4804/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944753595 CMS
Novartis Pharmaceuticals Corporation $21.4204/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893606237 CMS
EISAI INC. $15.8404/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908094485 CMS
Lilly USA, LLC $15.5504/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918372967 CMS
Merck Sharp & Dohme LLC $39.1404/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944776751 CMS
E.R. Squibb & Sons, L.L.C. $16.6403/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932785475 CMS
Myovant Sciences Inc. $16.1403/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941194995 CMS
Amgen Inc. $17.3103/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939880147 CMS
Astellas Pharma US Inc $14.5803/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940155331 CMS
Myovant Sciences Inc. $14.0003/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941194990 CMS
Novartis Pharmaceuticals Corporation $21.8603/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893606235 CMS
Janssen Biotech, Inc. $20.1803/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886549619 CMS
Genentech USA, Inc. $15.5603/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950794233 CMS
Merck Sharp & Dohme LLC $24.9203/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944750831 CMS
Rigel Pharmaceuticals, Inc. $12.9803/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962269797 CMS
Novartis Pharmaceuticals Corporation $23.4303/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893606239 CMS
Celgene Corporation $15.9703/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932785473 CMS
Amgen Inc. $19.2503/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939880159 CMS
Merck Sharp & Dohme LLC $19.0103/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944775983 CMS
Rigel Pharmaceuticals, Inc. $16.3803/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962266305 CMS
E.R. Squibb & Sons, L.L.C. $9.2103/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932785563 CMS
Incyte Corporation $20.7103/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942961833 CMS
AstraZeneca Pharmaceuticals LP $23.3103/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914649177 CMS
EISAI INC. $5.0403/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908094463 CMS
Astellas Pharma US Inc $17.4203/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940133571 CMS
Epizyme, Inc., $11.9003/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917607297 CMS
Merck Sharp & Dohme LLC $16.8202/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944749373 CMS
E.R. Squibb & Sons, L.L.C. $15.8802/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932785561 CMS
Novartis Pharmaceuticals Corporation $19.7202/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893606229 CMS
GENZYME CORPORATION $21.1002/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938761539 CMS
Janssen Biotech, Inc. $15.6502/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886549601 CMS
EISAI INC. $23.0102/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908094483 CMS
GENZYME CORPORATION $18.3802/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938761523 CMS
Novartis Pharmaceuticals Corporation $20.7202/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893606231 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,943.13 195
PY2020 $5,171.57 189
PY2021 $3,121.69 193
PY2022 $4,033.51 226
PY2023 $3,676.21 211
PY2024 $3,467.54 155
PY2025 $3,652.58 160

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $129,641.37 30
PY2024 Principal investigator $25,302.00 20
PY2023 Principal investigator $24,049.00 7
PY2022 Principal investigator $198,622.00 47
PY2021 Principal investigator $23,375.88 10
PY2020 Principal investigator $70,030.72 6
PY2019 Principal investigator $39,178.04 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 12/31/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744602
Principal investigator 1 Janssen Research & Development, LLC $4,734.00 12/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175327787
Principal investigator 1 PFIZER INC. $356.50 12/15/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228714360
Principal investigator 1 PFIZER INC. $23,590.88 12/15/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228714362
Principal investigator 1 PFIZER INC. $19,908.70 12/15/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228715039
Principal investigator 1 PFIZER INC. $461.25 12/15/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228715041
Principal investigator 1 PFIZER INC. $2,987.04 12/15/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228715043
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 11/30/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744600
Principal investigator 1 Janssen Research & Development, LLC $4,200.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175327731
Principal investigator 1 Janssen Research & Development, LLC $4,500.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175329263
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175329312
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175329402
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175329801
Principal investigator 1 Janssen Research & Development, LLC $2,684.00 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175327341
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,725.00 10/31/2025 Non-covered Recipient Entity
TENNESSEE CANCER SPECIALISTS, PLLC
a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer No dispute reported 06/30/2026 1185540009
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 10/31/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744598
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 09/30/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744576
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 09/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175329221
Principal investigator 1 Janssen Research & Development, LLC $17,000.00 09/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175329679
Principal investigator 1 Janssen Research & Development, LLC $11,719.00 09/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175327062
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 08/31/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744578
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 07/31/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744580
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 06/30/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744582
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 05/31/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744584
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 04/30/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744586
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 03/31/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744588
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 02/28/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744590
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $975.00 02/28/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744592
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 02/28/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744594
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5,000.00 01/31/2025 Non-covered Recipient Entity
Tennessee Cancer Specialists
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) No dispute reported 06/30/2026 1233744596